MSB Trading - 2020, page-12765

Pending 3 bloody cap raises this week I am really torn between injecting some more funds if we see a sustained recovery to $4. Given the timeline importance and the willingness of the FDA to fast track treatments for Covid19 patients there has got to be something coming down the pipeline very soon. First patients dosed in trial 6th May, 30 days from then = early June, surely a turnaround result would be noted inside the 30 days for the endpoints and a streamlined analysis due to the importance of roll out to curb mortality?
The primary endpoint is all-cause mortality within 30 days of randomization, with
the key secondary endpoint being the number of days alive and off mechanical support
Not that the pump on IMC should reflect anything on MSB, because we are pairing a minnow of 15million MC against a giant at over 2billion MC, but attention towards AU based biotech's will ring some bells on the Nasdaq where they are both listed. The common ground is both are partnered in their trials with US based bedfellows meaning they have larger exposure to all those investors following either the DoD involvement or the respected likes of US Cardiothoracic Surgical Trials Network.
MSB's candidate produced effective results within 5 days from dosing last time so give us the results already aAAHHHHH.
75% of patients of the ventilators within 10 days......